Andy Robbins is the founder of UNUM Therapeutics. UNUM Therapeutics has raised $181M in total funding. Latest round: Series B.
Andrew Robbins was appointed President and CEO of Cogent Biosciences (formerly Unum Therapeutics Inc.) in October 2020. Cogent Biosciences is a biotechnology company developing precision therapies for genetically defined diseases. Prior to this role, Robbins served as Chief Operating Officer at Array Biopharma, which was acquired by Pfizer in 2019.
Full founder directory · Investor directory · Company funding database · Fundraising library